

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PARDIGNON <i>et al.</i> , "Delayed and separate costimulation <i>in vitro</i> supports the evidence of a transient 'excited' state of CD8 <sup>+</sup> T cells during activation," <i>J. Immunol.</i> 164, 4493-99, 2000	
		BRUNMARK & O'ROURKE, "Augmentation of CD4 <sup>+</sup> T cell responses to isolated antigenic Class II proteins by Fibronectin and Intercellular Adhesion Molecule-1," <i>J. Immunol.</i> 159, 1676-85, 1997	
		GAY <i>et al.</i> , "The Major Histocompatibility Complex-restricted antigen receptor on T cells," <i>J. Immunol.</i> 136, 2026-32, 1986	
		MOTTA <i>et al.</i> , "In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density," <i>Eur. J. Immunol.</i> 28, 3685-95, 1998	
		MARTI <i>et al.</i> , "Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding MHC class II and costimulatory molecules," <i>J. Immunol. Methods</i> 200, 191-98, 1997	
		SPRENT <i>et al.</i> , "Constructing artificial antigen-presenting cells from <i>Drosophila</i> cells," <i>Dendritic Cells in Fundamental and Clinical Immunology</i> , Ricciardi-Castagnoli, ed., Plenum Press Publ, NY	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.